Organogenesis (NASDAQ:ORGO) Director Purchases $321,407.06 in Stock

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf acquired 107,494 shares of the company’s stock in a transaction dated Thursday, May 15th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $321,407.06. Following the completion of the transaction, the director directly owned 358,495 shares of the company’s stock, valued at approximately $1,071,900.05. This trade represents a 42.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Organogenesis Stock Down 5.9%

Shares of NASDAQ ORGO traded down $0.25 during mid-day trading on Monday, reaching $4.00. 1,648,527 shares of the company were exchanged, compared to its average volume of 1,276,991. The stock has a market capitalization of $507.43 million, a P/E ratio of -28.57 and a beta of 1.68. Organogenesis has a twelve month low of $2.61 and a twelve month high of $6.71. The company’s 50-day simple moving average is $4.48 and its 200-day simple moving average is $4.19.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The company had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on ORGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Cantor Fitzgerald increased their price target on shares of Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of Organogenesis in a report on Friday, September 26th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Organogenesis currently has an average rating of “Hold” and a consensus price target of $7.33.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds have recently modified their holdings of ORGO. First Light Asset Management LLC acquired a new position in shares of Organogenesis during the second quarter worth $24,804,000. Assenagon Asset Management S.A. lifted its holdings in shares of Organogenesis by 748.1% during the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock worth $10,460,000 after purchasing an additional 2,520,941 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Organogenesis during the first quarter worth $7,756,000. Invesco Ltd. lifted its holdings in shares of Organogenesis by 779.7% during the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock worth $4,619,000 after purchasing an additional 947,705 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after purchasing an additional 841,618 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.